M1FG
HRMY icon

Mach-1 Financial Group’s Harmony Biosciences HRMY Stock Holding History

Mach-1 Financial Group’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,769
Closed -$485K – 230
2023
Q2 		$485K Buy
+13,769
New +$475K 0.14% 152

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Mach-1 Financial Group's HRMY Position: Q3 2023 in Review

Mach-1 Financial Group sold out of Harmony Biosciences (HRMY) in Q3 2023, closing a stake of 13,769 shares — an estimated $485K sold.

Mach-1 Financial Group first reported a position in HRMY in Q2 2023 and held it in 1 quarter. The position peaked at $485K in Q2 2023. 204 funds tracked by Wall St. Rank hold HRMY as of Q3 2023.

  • Mach-1 Financial Group reported no remaining Harmony Biosciences position as of Q3 2023 after selling out during the quarter.
  • Mach-1 Financial Group sold 13,769 Harmony Biosciences shares in Q3 2023, an estimated $485K.
  • Mach-1 Financial Group first reported a position in Harmony Biosciences in Q2 2023 and held it in 1 quarter.
  • Mach-1 Financial Group's Harmony Biosciences position peaked at $485K in Q2 2023.
  • 204 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2023.

Based on Mach-1 Financial Group's 13F filing for Q3 2023, filed 17 Oct 2023.